

Exhibit C

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

Heraeus Medical GmbH,

Plaintiff,

v.

Esschem, Inc.,

Defendant.

Civil Action No. 2:14-cv-05169-CMR

**HERAEUS MEDICAL GMBH'S
INITIAL DISCLOSURES UNDER FED. R. CIV. P. 26(A)(1)**

The following initial disclosures are made by Plaintiff, Heraeus Medical GmbH (hereinafter "Heraeus"), in accordance with Fed. R. Civ. P. 26(a)(1). Heraeus' initial disclosures are made subject to the limitations and exceptions set forth below.

LIMITATIONS AND EXCEPTIONS

1. Discovery has not commenced in this case. Heraeus therefore reserves the right to make subsequent disclosures, amend these disclosures, use documents not described, and rely on witnesses not identified as additional information becomes available during the course of discovery.

2. The questions of whether the Heraeus specifications are protectable trade secrets that were misappropriated and used by third party Biomet, Inc. and its affiliates (collectively, "Biomet") are issues of German law that have been fully and finally determined by a German court of competent jurisdiction. As a result, those issues should not be re-litigated in this case, and Defendant, Esschem, Inc. ("Esschem") should not be permitted to take burdensome and irrelevant discovery into those issues.

3. In making these initial disclosures, Heraeus is not waiving any objections to admissibility based upon relevance, materiality, competence, privilege, immunity, or any other objection that may be available under applicable rules of law.

DISCLOSURES

1. Names of Individuals Likely to Have Discoverable Information

Based on information currently available to Heraeus, each of the individuals listed below may have discoverable information that Heraeus may use to support its claims. Individuals (a) – (c) are employees or former employees of Heraeus. Dr. Klinkert is Heraeus' counsel in Europe. Heraeus does not consent to or authorize Defendant or its counsel to communicate with any of these individuals directly. Any such individual must be contacted only through Heraeus' undersigned counsel.

- (a) Karl-Wilhelm Schneider, Heraeus in-house attorney responsible for bone cement litigation – information claimed as Heraeus' trade secrets, steps taken to protect Heraeus' trade secrets.
- (b) Dr. André Kobelt, CEO of Heraeus Medical GmbH – Heraeus' history as a leader in the bone cement industry, business lost as a result of Biomet's and Esschem's misappropriation of Heraeus' trade secrets; bone cement industry, use of bone cements by doctors; Heraeus' damages as a result of Esschem's misappropriation, business loss from Biomet's and Esschem's misappropriation of Heraeus' trade secrets.
- (c) Dr. Thomas Kluge, Head of Technology of Heraeus Medical GmbH – history of the development of Heraeus' bone cements; technical details of Heraeus' bone cements and its trade secrets; features of Heraeus' bone cements and other bone cements in the industry. Heraeus reiterates that the determinations in the

Frankfurt Judgment about the Heraeus trade secrets is binding in this action that thus any attempt to re-litigate this issue is improper. Heraeus may call Dr. Kluge at the preliminary injunction hearing to testify about the industry, substitutability of Heraeus' products, and the public interest factor.

- (d) Friedrich Klinkert – litigation of Heraeus' trade secret claims worldwide.

Individuals affiliated with Esschem

- (e) Edward Sobolewski – research, development, composition and structure of R262 and R263.
- (f) Phon Malone – research, development, composition and structure of R262 and R263.
- (g) Michael Norquist – research, development, composition and structure of R262 and R263.
- (h) Henry Justi – research, development, composition and structure of R262 and R263.

Individuals affiliated with Biomet

- (i) Rainer Specht – research, development, composition and structure of R262 and R263; disclosure of Heraeus trade secrets to Esschem.
- (j) Daniel Smith – research, development, composition and structure of R262 and R263; disclosure of Heraeus trade secrets to Esschem.
- (k) Robert Ronk – research, development, composition and structure of R262 and R263; disclosure of Heraeus trade secrets to Esschem.
- (l) Daniel Hann – disclosure of Heraeus trade secrets to Esschem.
- (m) Dane Miller – disclosure of Heraeus trade secrets to Esschem.
- (n) Judy Fenton – bone cement industry, use of bone cements by doctors.

2. Description by Category and Location of Documents That May be Used to Support Heraeus' Claims

After a reasonable inquiry, Heraeus believes that the following categories of documents and things may be used to support its claims.

- (a) The decision of the Frankfurt Court of Appeals – Germany.
- (b) Sales and marketing of Heraeus' bone cements – Germany.
- (c) Research, development, composition and structure of R262 and R263 – location unknown, but believed to be at Esschem's facility in Pennsylvania.
- (d) Esschem's knowledge that the information provided by Biomet was trade secret information belonging to Heraeus and any opinions of counsel regarding these issues – location unknown, but believed to be at Esschem's facility in Pennsylvania and/or Biomet's facilities in Indiana or elsewhere.
- (e) Discussions between Biomet and Esschem and Esschem and any third parties regarding Heraeus' trade secrets – location unknown, but believed to be at Esschem's facility in Pennsylvania and/or Biomet's facilities in Indiana or elsewhere.
- (f) Manufacturing of R262 and R263 – location unknown, but believed to be at Esschem's facility in Pennsylvania and/or Biomet's facilities in Indiana or elsewhere.
- (g) Distribution of R262 and R263 – location unknown, but believed to be at Esschem's facility in Pennsylvania and/or Biomet's facilities in Indiana or elsewhere.
- (h) Sales of R262 and R263 – location unknown, but believed to be at Esschem's facility in Pennsylvania and/or Biomet's facilities in Indiana or elsewhere.

3. Computation of Damages

Heraeus has suffered and continues to suffer damages in an amount yet to be determined as a result of Esschem's ongoing use of Heraeus' trade secrets to produce and distribute R262 and R263. Damages, including interest and costs, are authorized and recoverable under the Pennsylvania Uniform Trade Secret Act. Heraeus is entitled to recover both the actual loss caused by misappropriation and the unjust enrichment caused by misappropriation that is not taken into account in computing actual loss. Alternatively, Heraeus may recover a reasonable royalty for Esschem's unauthorized use of Heraeus' trade secrets. The amount of damages attributable to Esschem's misconduct will be determined in the course of fact and expert discovery in this case, after complete sales and other information is produced.

4. Applicable Insurance Agreements

At this time, Heraeus is not aware of any such insurance agreements applicable to the types of damage and amounts in question.

February 6, 2015

Respectfully submitted,

Samuel W. Silver (Pa. Bar No. 56596)
John R. Timmer (Pa. Bar No. 89814)
Schnader Harrison Segal & Lewis LLP
1600 Market Street, Suite 3600
Philadelphia, PA 19103-7286
Phone: (215) 751-2309
Fax: (215) 751-2205

*Attorneys for Plaintiff
Heraeus Medical GmbH*

/s/ Lawrence D. Rosenberg
Lawrence D. Rosenberg (Pa. Bar No. 67414)
JONES DAY
51 Louisiana Avenue, NW
Washington, DC 20001
Phone: (202) 879-3939
Fax: (202) 626-1700

Susan M. Gerber (Ohio Bar No. 0070945)
JONES DAY
North Point, 901 Lakeside Avenue
Cleveland, OH 44114
Phone: (216) 586-3939
Fax: (216) 579-0212

CERTIFICATE OF SERVICE

I hereby certify that on this 6th day of February, 2015, I caused a true and correct copy of the foregoing *Heraeus Medical GmbH's Initial Disclosures Under Fed. R. Civ. P. 26(A)* to be served upon counsel of record for Esschem, Inc. by email in accordance with the parties service agreement as follows:

esschem-gt@gtlaw.com
mplatt@finemanlawfirm.com

/s/ Susan M. Gerber
Susan M. Gerber